Granitov V.M, Karbysheva N.V, Sultanov L.V, McCausland C, Oganova E.
The Altay State Medical University;
The Altay Regional Center for Prophylaxis and Treatment of AIDS, Russian Federation
INTRODUCTION : Included in this study were 25 HIV-infected patient (20 male and 5 female), ages 19 to 56 (15 patient ages 21-25). Individuals were classified to V.I Pokrovsky’s classification (1989) for HIV infection. Eight (8) were diagnosed to have stage 2B, thirteen (13) patient were stage 2C, three (3) patients were stage 3A and one (1) was stage 3B. Infection periods were as follows : (9) patients were infected 1 year ago, four (4) were 2 years ago, four (4) were three years ago, six (6) were five years ago, and two (2) were six years ago.
OBJECTIVE : The purpose of this study is to serve as an initial trial in evaluating the effects of enhanced transfer factors supplementation on HIV-Infected patients.
METHODOLOGY : The experimental group (15 patients), who did not receive antiretroviral or immuno-correcting theraphy, received enhanced transfer factors provided by 4LifeResearch, USA. They were adminitered one capsule twice a day for 7 days. The control group (10 patients) consisted of HIV-infected patients taking cycloferon in the following dosage schedule : 1st, 2nd, 4th, 6th, 8th, 10th, 12th, dan 14th days. Before treatment and 7 to 10 days after the treatment an evaluation was carried out to access the immune status of the patient groups and to determine cytokine (interleukin 1 (IL-1), tumor necrosis factor (TNF-) and interferon (IFN) levels.
RESULTS : In the experimental group, it was found that after treatment with enhanced transfer factors there was an increase of lympocytes in 13 patients, an increase of CD3 cells in 15 patients, and increase of CD4 cells in 14 patients and an increase in CD8 cells in 12 patients. Immuno-regulating index (IRI) persisted on the same level in 3 patients was increased in 10 patients and decreased in 7 patients. IgG was reduced in 16 patients and IgM was within normal limits in all patients. An Increase of IL-1 and IFN-7 was noted in all patients treated with transfer factor. Ciruculating Immune Complex (CIC) levels dropped to normal levels in 10 of the patients. In the control group an increase of lymphcytes was noted in only 3 patients. A decrease of CD3,CD4 and CD8 cells was noted in 6 patients. IRI persisted on the same level or decreased. CIC levels dropped to normal in 3 patients, increased in 6 patients, there was no change in 1 patient. The Occurence of Increases and decreases of IgG were equal.
CONCLUTION : We conclude that transfer factors therapy considerably improves the immune status of HIV-infected patients and can be recommended in combating the pathogenesis of the disease.